Drug
ALKS 5461 clinical trials
Also written ALKS 5461.
- studies test it
- 17
- open now
- 0
- in phase 3
- 7
- first study started
- 2011
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
17 studies that test it; most in 2014 (7)
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2014 | 7 |
| 2015 | 6 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 2
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 0
Studies
Open first, then newest update. How each study uses ALKS 5461 is read from its arms, and is right about nine times in ten.
Testing it · 17
- A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)TerminatedPhase 3Alkermes, Inc.NCT03610048Written as ALKS 5461
- A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)CompletedPhase 3Alkermes, Inc.NCT03188185Written as ALKS 5461
- A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)CompletedPhase 3Alkermes, Inc.NCT02085135Written as ALKS 5461
- A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 StudyCompletedPhase 3Alkermes, Inc.NCT02218008Written as ALKS 5461
- A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 StudyCompletedPhase 3Alkermes, Inc.NCT02158533Written as High Dose ALKS 5461
- A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 StudyCompletedPhase 3Alkermes, Inc.NCT02158546Written as ALKS 5461
- A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)CompletedPhase 2Alkermes, Inc.NCT01500200Written as ALKS 5461
- A Long-Term Safety Study of ALKS 5461CompletedPhase 3Alkermes, Inc.NCT02141399Written as ALKS 5461
- Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic FunctionCompletedPhase 1Alkermes, Inc.NCT02452801Written as ALKS 5461
- Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal FunctionCompletedPhase 1Alkermes, Inc.NCT02508506Written as ALKS 5461
- A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy VolunteersCompletedPhase 1Alkermes, Inc.NCT02479308Written as ALKS 5461
- A Water Consumption Study of ALKS 5461 in Healthy VolunteersCompletedPhase 1Alkermes, Inc.NCT02521857Written as ALKS 5461
- A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid UsersCompletedPhase 1Alkermes, Inc.NCT02413281Written as ALKS 5461
- A Drug-drug Interaction Study of ALKS 5461 in Healthy VolunteersCompletedPhase 1Alkermes, Inc.NCT02545439Written as ALKS 5461
- A Drug-Drug Interaction Study of ALKS 5461 in Healthy VolunteersCompletedPhase 1Alkermes, Inc.NCT02272764Written as ALKS 5461
- A Study of ALKS 5461 in Healthy VolunteersCompletedPhase 1Alkermes, Inc.NCT02068105Written as ALKS 5461
- ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDDCompletedPhase 1/2Alkermes, Inc.NCT01381107Written as ALKS 5461